RoyMitchelFleischmannMD
Rheumatology • Dallas, TXClinical Professor of Medicine, University Tex SW Dallas
Dr. Fleischmann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8144 Walnut Hill Ln
Suite 800
Dallas, TX 75231Phone+1 214-540-0700Fax+1 214-540-0701
Summary
- Board certified rheumatologist
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Rheumatology, 1973 - 1974
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1971 - 1972
Maimonides Medical CenterResidency, Internal Medicine, 1969 - 1971
State University of New York Downstate Medical Center College of MedicineClass of 1969
Certifications & Licensure
TX State Medical License 1975 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Master of the American College of Rheumatology ACR, 2009
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
Clinical Trials
- ETEC Logistics Trial (TREK) Start of enrollment: 2006 May 01
- An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2013 Jun 27
- A Study of LY3337641 in Rheumatoid Arthritis Start of enrollment: 2016 Aug 22
- Join now to see all
Publications & Presentations
PubMed
- 149 citationsPoints to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.Peter Nash, Andreas Kerschbaumer, Thomas Dörner, Maxime Dougados, Roy Fleischmann
Annals of the Rheumatic Diseases. 2021-01-01 - 149 citationsPotential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.Christina Charles-Schoeman, Roy Fleischmann, Jean Davignon, Howard Schwartz, Scott M. Turner
Arthritis & Rheumatology. 2015-03-01 - 92 citationsA novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 studyYusuf Yazici, Timothy E. McAlindon, Roy Fleischmann, Allan Gibofsky, Nancy E Lane
Osteoarthritis and Cartilage. 2017-10-01
Authored Content
- Interpreting the Results of ORAL-Surveillance at ACR 2021November 2021
Press Mentions
‘Pristine’ Safety Profile Sets TYK2i Apart from JAK ‘Baggage’ in Psoriatic Disease, LupusAugust 16th, 2024- AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (Upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 CongressMay 24th, 2023
- All or Something: Experts Debate LDA vs. Remission as a Target in Rheumatoid ArthritisApril 19th, 2022
- Join now to see all
Professional Memberships
- Member
- Master Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
